bioRxivCancer BiologyPreprint
Global kinome silencing combined with 3D invasion screening of the tumor microenvironment identifies fibroblast-expressed PIK3Cδ involvement in triple-negative breast cancer progression
T. Gagliano, K. Shah, S. Gargani, L. Lao, M. Alsaleem, J. Chen, V. Ntafis, P. Huang, A. Ditsiou, V. Vella, K. Yadav, K. Bienkowska, G. Bresciani, K. Kang, L. Li, P. Carter, G. Benstead-Hum, T. O'Hanlon, M. Dean, F. M. G. Pearl, S.-C. Lee, E. A. Rakha, A. R. Green, D. L. Kontoyiannis, E. Song, , G. Giamas
Abstract
As there is growing evidence for the tumor microenvironments (TME) role in tumorigenesis, we sought to investigate the role of fibroblast-expressed kinases in triple negative breast cancer (TNBC). Using a high-throughput kinome screen combined with 3D invasion assays, we identified fibroblast-expressed PIK3C{delta} (f-PIK3C{delta}) as a key regulator of progression. Although PIK3C{delta} has been mainly described in leucocytes, we detected high expression in primary fibroblasts derived from TNBC patients, while PIK3C{delta} was undetectable in cancer epithelial cell lines. Genetic and pharmacologic gain- and loss-of functions experiments verified the contribution of f-PIK3C{delta} in TNBC cell invasion. By employing an integrated secretomics and transcriptomics analysis, we revealed a paracrine mechanism via which f-PIK3C{delta} confers its pro-tumorigenic effects. Inhibition of f-PIK3C{delta} promoted the secretion of factors, including PLGF and BDNF, which subsequently led to upregulation of NR4A1 in TNBC cells where it acts as a tumor suppressor. Inhibition of PIK3C{delta} in an orthotopic BC mouse model reduced tumor growth only after inoculation with fibroblasts, indicating a role of f-PIK3C{delta} in cancer progression. Similar results were observed in the MMTV-PyMT transgenic BC mouse model, in addition to a decrease on tumor metastasis emphasizing the potential immune-independent effects of PIK3C{delta} inhibition. Finally, analysis of BC patient cohorts and TCGA datasets identified f-PIK3C{delta} (protein and mRNA levels) as an independent prognostic factor for overall and disease free survival, highlighting it as a therapeutic target for TNBC.
- organism: mouse
- assay: proteomics
- assay: metabolomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodeling of the extracellular matrix
Anna Yui, Liyi Peng, … Madeleine Julie Oudin·bioRxiv·Sep 8, 2026
- Combined agonism and antagonism of canonical and non-canonical progesterone receptors in triple-negative breast cancer cells potentiates cytotoxicity enhanced by PI3K inhibition
Paula E. Petrella, Jason W. Chen, Benjamin D. Cosgrove·bioRxiv·Jun 26, 2026
- Fibronectin, DHPS and SLC3A2 Signaling Cooperate to Control Tumor Spheroid Growth, Subcellular eIF5A1/2 Distribution and CDK4/6 Inhibitor Resistance
C. Geller, J. Maddela, … J. A. Kelber·bioRxiv·Apr 13, 2023
- Loss of PKCtheta-GADD45a axis drives triple-negative breast cancer cells into p53-independent senescence
Amandine Nicolle, Ye Zhang, … Karine Belguise·bioRxiv·Oct 10, 2024
- CD95 expression in triple negative breast cancer blocks induction of an inflammatory state through differential regulation of NF-kB Signaling
J.-P. Guegan, J. Pollet, … P. Legembre·bioRxiv·Apr 7, 2021
- On the therapeutic potential of MAPK4 in triple-negative breast cancer
F. Boudghene-Stambouli, M. Soulez, … S. Meloche·bioRxiv·Aug 24, 2022